PA SB946

Adds tianeptine to Pennsylvania's Schedule II controlled substances list, placing it alongside opioids and cocaine as a drug with high abuse potential and severe dependence risk

Requires the Department of Health to monitor adverse health events associated with tianeptine by collecting data from health care providers, hospitals, poison control centers, coroners, medical examiners, and law enforcement

Mandates the department issue public advisories when tianeptine-related adverse events or usage trends pose significant threats to public safety

Defines adverse health events broadly to include neurological, respiratory, cardiovascular, psychological, gastrointestinal, and withdrawal symptoms, as well as any fatal or life-threatening reactions from tianeptine exposure

Takes effect 60 days after enactment